Brief: Mesoblast Ltd Posts Gross Revenue Of $21.9 Million On Ryoncil Sales For Quarter
07/10/2025 02:36
Oct 7 (Reuters) - Mesoblast Ltd MSB.AX: GROSS REVENUE OF $21.9 MILLION ON RYONCIL SALES FOR QUARTER Further company coverage: MSB.AX ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Mesoblast
See all newsBrief: Mesoblast Reports QTRLY Ryoncil Net Revenues Of $30.3 Million
ASX-shares of Mesoblast rise after back-treatment drug hits patent target
Australia's Mesoblast soars on bagging licence for Mayo Clinic-developed tech
Brief: Mesoblast Acquires CAR Platform For Precision-Enhanced Cell Products
Brief: Mesoblast Says Ryoncil's Net Revenue For Quarter Increases To US$30.3M